Greenwich LifeSciences, Inc.: Business Overview, Financials & Competitive Analysis
Greenwich LifeSciences, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Potential value inflection point if FLAMINGO-01 trial delivers statistically significant recurrence reduction, enabling regulatory pathway and commercial opportunity in large HER2+ breast cancer market. The company possesses differentiated Phase IIb efficacy data (80%+ vs 50% for competitors) and FDA manufacturing approval, providing validation for progression. However, as a clinical-stage.
What is Greenwich LifeSciences, Inc.'s industry? Greenwich LifeSciences, Inc. (greenwichlifesciences.com) operates in Biopharmaceutical / Immuno-Oncology. AskCyborg classifies Greenwich LifeSciences, Inc. under Biopharmaceutical / Immuno-Oncology in its company registry.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GP2, an immunotherapy candidate designed to prevent breast cancer recurrence in HER2-positive patients who have undergone surgery. The co...
Cyborg Score thesis
Potential value inflection point if FLAMINGO-01 trial delivers statistically significant recurrence reduction, enabling...
Read the full analyst-debate transcript →Get the Latest Greenwich LifeSciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGreenwich LifeSciences, Inc. Overview
Pro stress-test →Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GP2, an immunotherapy candidate designed to prevent breast cancer recurrence in HER2-positive patients who have undergone surgery. The company's lead program, FLAMINGO-01, is a Phase III global trial spanning 150+ clinical sites across the US and Europe, with interim analysis planned for a 70% reduction in metastatic recurrence.
Strategic Profile
Pro stress-test →The company positions GP2 as a potential breakthrough therapy with Phase IIb data showing 80%+ reduction in recurrence rates, significantly exceeding the ~50% achieved by existing HER2-targeted therapies like Herceptin and Kadcyla. With FDA approval of the first commercial manufacturing lot received in January 2026 and recent capital raises maintaining ~$12.5M in cash, Greenwich LifeSciences is executing a capital-efficient approach while advancing toward pivotal trial completion.
Competitive Landscape
Pro stress-test →Greenwich LifeSciences competes in the HER2-targeted breast cancer therapeutic space against established players with approved recurrence-prevention therapies. Direct competitors include Roche/Genentech (Herceptin/trastuzumab), Eli Lilly (Kadcyla/ado-trastuzumab), and other immuno-oncology companies developing preventative approaches. GP2's proposed mechanism and Phase IIb efficacy data position it as a potential best-in-class candidate if Phase III validation succeeds.
Industry Context
Greenwich LifeSciences, Inc. operates in Biopharmaceutical / Immuno-Oncology.
Key facts
Headquarters: Stafford, Texas, United States · Revenue: $0